Loading
VB
Viva Biotech Holdings Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Wu Ying, was filed 14 Jun 2023.
Viva Biotech Holdings: what insiders have been doing
Every trade that managers of Viva Biotech Holdings disclose to HKEX is tracked on this page. The company sits in the Health Care sector. In the past year (22 October 2025 to 22 October 2026), 5 filings came from 3 insiders.
All open-market trades in the period are sales: 5 sales, by 3 insiders, with no purchase on record. The totals do not cover 5 filings with an undisclosed amount.
Typically, a trade is published a median of 1 day after it takes place. That lag is the time during which only the insider knows about the trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 5 filings in twelve months, the company is more active than the median of 4 filings across the 1,314 companies we follow on the same exchange. The full history, which starts in 2019, counts 21 purchases against 27 sales.
These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.
Insider Decl.
90
Thresholds
n/a
Buy Volume
€3M
21 ops. · all time
Sell Volume
€35M
27 ops. · all time
Who traded when
BuySaleRen Delin4 sales
Wu Ying4 sales
Mao Chen Cheney2 sales
Since the insiders bought
- -67.8%Entry HK$1.74 · Close at T+365 HK$0.56
- -23.1%Entry HK$7.95 · Close at T+365 HK$6.11
- -19.8%Entry HK$7.62 · Close at T+365 HK$6.11
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,404 of 26,250 companies
64.5
score / 100
Value73
Quality56
FCF yld4.2%
Earn yld8.3%
EV/EBITDA7.0x
ROE5.6%
Gross mgn38%
Net mgn13%
Debt/EBITDA2.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$1.28
Analyst consensus
1 analystsHK$2.89Target HK$2.89(+126%)HK$2.89
Income statement
RevenueHK$1.7B
Gross profitHK$655.6M38% margin
EBITDAHK$566.6M33% margin
Net incomeHK$219.8M9.4% margin
Valuation
PER (trailing)16.0x
P/Book0.6x
Beta1.31
Balance sheet & cash
Market capHK$2.6B
Total debtHK$1.3B
Free Cash FlowHK$109.7M
Debt / Equity23%
Profitability & ownership
ROE5.6%
ROA1.7%
% insiders43.5%
% institutions8.6%
Last declaration on 7 July 2026
Declarations90 total
640,000 sharesShareXHKGHKEX:DA20260707E00491
640,000 sharesShareXHKGHKEX:DA20260707E00461
640,000 sharesShareXHKGHKEX:DA20260707E00444
512,000 sharesShareXHKGHKEX:DA20260102E00548
512,000 sharesShareXHKGHKEX:DA20260102E00547
640,000 sharesShareXHKGHKEX:DA20250110E00614
640,000 sharesShareXHKGHKEX:DA20250110E00623
800,000 sharesShareXHKGHKEX:DA20250110E00619
768,000 sharesShareXHKGHKEX:DA20250102E00023
768,000 sharesShareXHKGHKEX:DA20250102E00021
32,790,526 sharesShareXHKGHKEX:DA20240603E00264
19,750,992 sharesShareXHKGHKEX:DA20240508E00484
85,000,000 sharesShareXHKGHKEX:DA20240307E00011
117,209,474 sharesShareXHKGHKEX:DA20240108E00432
75,000,000 sharesShareXHKGHKEX:DA20240105E00462
458,323,527 sharesShareXHKGHKEX:DA20231123E00216
60,000 shares@ HK$1.60670.6% of flowShareXHKGHKEX:DA20230614E00333
Canonical exit: 12 Sept 2023 (T+90)
140,000 shares@ HK$1.61571.4% of flowShareXHKGHKEX:DA20230614E00221
Canonical exit: 11 Sept 2023 (T+90)
100,000,000 sharesShareXHKGHKEX:DA20221221E00370
50,000,000 sharesShareXHKGHKEX:DA20220602E00062
5,266,931 sharesShareXHKGHKEX:DA20220126E00355
10,000,000 sharesShareXHKGHKEX:DA20211231E00044
1,280,000 sharesShareXHKGHKEX:DA20211206E00024
Canonical exit: 2 Mar 2022 (T+90)
1,280,000 sharesShareXHKGHKEX:DA20211206E00022
Canonical exit: 2 Mar 2022 (T+90)
15,000,000 sharesShareXHKGHKEX:DA20211108E00161
25 of 90 declarations
About Viva Biotech Holdings
Viva Biotech Holdings is a company listed on the Hong Kong Stock Exchange, specializing in biopharmaceutical solutions. It focuses on the research and development of innovative drugs.
